Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings yield is N/A as of 2026-10-06T22:19:21.844Z.
Calculation as of: 2026-10-06T22:19:21.844Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4bd4e0dbd4a7a93fa478f826dfbb4c5faa0838165ed73afdd7809c26b653191f
EARNINGS YIELD
N/A
WORK Medical Technology Group Ltd. Class A
Market Cap
$3.63M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.53M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.90M
Earnings Yield
N/A
TTM Avg
13.10%
3Y Avg
13.10%
5Y Avg
13.10%
Market Cap
$3.93M
Earnings Yield
N/A
TTM Avg
120.37%
3Y Avg
120.37%
5Y Avg
120.37%
| NAME | MARKET CAP | EARNINGS YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| WORK Medical Technology Group Ltd. Class A (WOK) | $3.63M | N/A | N/A | N/A | N/A |
| Ernexa Therapeutics Inc. (ERNA)vs › | $3.65M | N/A | N/A | N/A | N/A |
| Evogene Ltd. (EVGN)vs › | $3.65M | N/A | N/A | N/A | N/A |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.53M | N/A | N/A | N/A | N/A |
| Moolec Science S.A. (MLEC)vs › | $3.50M | N/A | N/A | N/A | N/A |
| Eocene Ltd. (EOCN)vs › | $3.50M | N/A | N/A | N/A | N/A |
| Mustang Bio, Inc. (MBIO)vs › | $3.49M | N/A | N/A | N/A | N/A |
| 60 Degrees Pharmaceuticals, Inc. (SXTP)vs › | $3.90M | N/A | 13.10% | 13.10% | 13.10% |
| Aptevo Therapeutics Inc. (APVO)vs › | $3.93M | N/A | 120.37% | 120.37% | 120.37% |
| Nexalin Technology, Inc. (NXL)vs › | $3.30M | N/A | N/A | N/A | N/A |
Earnings Yield
N/A
EPS ÷ Price
P/E Ratio
N/A
Price ÷ EPS
Formula: Earnings Yield = (EPS / Price) × 100
Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.
How earnings yield is used:
Earnings Yield = EPS (TTM) / Share Price
Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
